Table 1.
Summary of the participants in the study
| Dataset identifier | Source | Clinical diagnosis | Number | Age | M/F | Methods |
|---|---|---|---|---|---|---|
| #1 | NCT00928304† | yHC | 65 | 27.4 ± 5.1 | 25/40 | Sample of yHC (20–40 yrs) that underwent a 18F-florbetaben PET scan. This subset was used to develop an SUVR cutoff for early Aβ accumulation. |
| #2 | NCT00750282 [13] |
eHC AD |
66 73 |
68.0 ± 6.9 71.0 ± 7.9 |
28/38 41/32 |
All subjects underwent a 18F-florbetaben PET scan. This subset was used to develop an SUVR cutoff for established Aβ pathology using ROC analysis. |
| #3 | EudraCT: 2014-000798-38 [26] | SCD | 168 | 64.9 ± 7.3 | 65/103 | SCD patients from the Fundació ACE Healthy Brain Initiative (FACEHBI) study that underwent two 18F-florbetaben PET scans at baseline and after 2 years. This subset was used to assess the Aβ accumulation over time. |
| #4 | NCT01138111 [18] | MCI | 44 | 72.6 ± 6.6 | 28/16 | MCI subjects that underwent three 18F-florbetaben PET scans at baseline (n = 44), 1 yr (n = 40), and 2 yrs (n = 35) and a 4-year clinical follow-up. This subset was used to assess the Aβ accumulation over time and conversion to AD. |
| #5 | NCT02854033 (ADNI3‡) |
eHC MCI AD |
157 85 28 |
70.6 ± 6.1 71.7 ± 8.1 71.3 ± 7.0 |
62/95 47/38 18/10 |
Subjects from the ADNI3 study that underwent a 18F-florbetaben PET and a 18F-flortaucipir PET. This subset was used to assess the association between Aβ and tau deposition. |
†Unpublished methods on the sample of yHC are provided in the supplemental material 1
‡Part of the data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment and early Alzheimer’s disease. For up-to-date information, see www.adni-info.org
Abbreviations: yHC young healthy controls, eHC elderly healthy controls, AD Alzheimer’s disease dementia, SCD subjective cognitive decline, MCI mild cognitive impairment, SUVR standardized uptake value ratio, PET positron emission tomography, M male, F female, Aβ amyloid-beta, ROC receiver operating characteristic